Evidence map›Paper›PMID 38265099›Full record

ReviewTurk patoloji dergisi2024

Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature.

Manasi Mundada, Khalid Abdul Mannan, Divya Vasu, Faiq Ahmed, Suseela K

Abstract readCase ReportsReview
In one paragraph

Review in Turk patoloji dergisi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manasi MundadaDepartment of Pathology, Basavatarakam Indo American Cancer Hospital & Research Institute, HYDERABAD, INDIA.
Khalid Abdul MannanDepartment of Pathology, Basavatarakam Indo American Cancer Hospital & Research Institute, HYDERABAD, INDIA.
Divya VasuDepartment of Pathology, Basavatarakam Indo American Cancer Hospital & Research Institute, HYDERABAD, INDIA.
Faiq AhmedDepartment of Pathology, Basavatarakam Indo American Cancer Hospital & Research Institute, HYDERABAD, INDIA.
Suseela KDepartment of Pathology, Basavatarakam Indo American Cancer Hospital & Research Institute, HYDERABAD, INDIA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a highly malignant neoplasm with an undifferentiated or rhabdoid phenotype, posing a diagnostic challenge. This case report aims to create awareness about this rare neoplasm while dealing with cases presenting with undifferentiated morphology. CASE REPORT: A 55-year-old gentleman with constitutional symptoms and lymphadenopathy. Imaging revealed a mass lesion in the right upper lobe of the lung. A biopsy of the cervical lymph node showed diffusely effaced architecture replaced by sheets of undifferentiated pleomorphic cells with vesicular nuclei, prominent nucleoli, eosinophilic cytoplasm, and multiple necrotic foci. An extensive immunohistochemistry (IHC) panel was applied, which showed positivity for synaptophysin, vimentin, and focal CD34 and EMA expression. Other markers like pan-cytokeratin, p40, TTF1, CD56, INSM1, calretinin, CD45, SOX10, S100, CD30, CD117, SMA, and Desmin were negative, with INI1 retained. The IHC panel excluded the morphological differentials of carcinoma, lymphoma, rhabdomyosarcoma, melanoma, and germ cell tumor. Further literature review led to the possibility of the SMARCA4-UT entity, which had a morphology and IHC profile similar to the present case. Testing for SMARCA4 (BRG-1) by IHC showed a complete loss in the tumor cells, favoring the diagnosis of Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT).

conclusionSMARCA4-UTs are rare, highly aggressive, and poorly differentiated thoracic tumors. Recognizing them is vital as there is potential for therapeutic interventions such as immunotherapy and SMARCA4-targeted therapies, offering promising prospects for the future.

Indexed as

Biomarkers, TumorDNA HelicasesNuclear ProteinsTranscription FactorsHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedThoracic NeoplasmsBiomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors

Identifiers

PMID38265099
PMCPMC11131568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.